Epic Medical Research Joins hyperCORE International to Enhance Clinical Trials

Summary
Full Article
Epic Medical Research, a Dallas-based clinical research organization with 12 state-of-the-art locations, has officially joined hyperCORE International's global partner site network. This partnership is set to significantly enhance the scope and efficiency of clinical trials across a wide range of therapeutic areas, including metabolic disorders, fatty liver disease, and neurological conditions.
Dr. Haresh Boghara, President & Principal Investigator at Epic Medical Research, shared his enthusiasm for the collaboration, emphasizing the shared goal of advancing clinical research and improving patient outcomes. The alliance with hyperCORE International is anticipated to grant Epic access to greater resources and a more extensive platform for delivering innovative clinical trial solutions.
Nicholas Focil, President of hyperCORE International, praised Epic Medical Research for its comprehensive therapeutic focus and operational scale, highlighting the synergy with hyperCORE's mission to improve trial performance across its network. This partnership is expected to streamline operations and accelerate the delivery of clinical research results, leveraging the combined expertise and resources of both entities.
Since its inception in 2019, hyperCORE International has grown into a network of premier clinical research site organizations, boasting over 80 active trial sites in five countries. The network's collaborative model, centered on efficiency, standardization, and excellence, has successfully completed more than 7,000 studies with over 140,000 participants. The inclusion of Epic Medical Research into hyperCORE's network further solidifies its dedication to propelling clinical research forward through strategic collaborations.
For further details on hyperCORE International and its endeavors, visit https://www.hypercoreinternational.com.

This story is based on an article that was registered on the blockchain. The original source content used for this article is located at 24-7 Press Release
Article Control ID: 135975